| X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies for infectious diseases. Co.'s key product candidate, ASN100, is a monoclonal antibody therapeutic in clinical development for the prevention of Staphylococcus aureus pneumonia. Co.'s preclinical pipeline is comprised of monoclonal antibodies (mAbs) targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus (RSV). Co.'s ASN500 program is comprised of mAbs targeting RSV, which Co. is developing for the prevention of RSV infection. Co.'s Gram-negative programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. We show 5 historical shares outstanding datapoints in our ASNS shares outstanding history coverage, used to compute ASNS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ASNS market cap history over the course of time is important for investors
interested in comparing ASNS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ASNS versus a peer is one thing; comparing
ASNS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ASNS can fluctuate over the course of history.
With this page we aim to empower investors researching ASNS by allowing them to research the ASNS market cap history.